Fundraising in Israel and the United States - In this episode, I have a conversation with Tuvik Beker, CEO of Pangea Biomed, who has started, developed, and exited companies in the United States and Israel. Now he is developing Pangea Biomed to start the next revolution in precision oncology. Tuvik Beker is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last twenty years building, scaling, and leading companies in the healthcare, financial, and aerospace domains. Founded in 2018, Pangea Biomed is an Israeli biotech startup redefining cancer care. The company developed ENLIGHT - the world's most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. ⭐In this episode, we talk about: The Startup Ecosystem in Israel Fundraising in the United States from 2000 to 2022 3 Success Secrets to Fundraising in the US Precision Oncology The Enlight Technology Youtube 🎤 Quotes: (11:58) “Nothing is Impossible" (31:05) “The Abundance of Capital is one important factor. Another one is, how the area around Stanford University welcomes immigration and foreign innovation." (35:33) “Many US Investors invest only in US companies” (40:26) “"If you want to succeed in fundraising, you need to have a wide funnel. You need to start talking to many, many venture capitalists to close a round." (44:21) “Be mentally ready to have 100 meetings or more to get the initial cheque.” (50:30) "The most important thing to bear in mind is building honest relationships with venture capitalists." (01:14:06) “Pangeas approach focuses on harnessing these expression abnormalities in order to attack cancer cells and spare normal healthy cells.” 🕛 Timestamps: (00:00) Opening (05:32) The Origin of Pangea Biomed (07:45) The Startup Ecosystem in Israel (10:16) Conversation Culture in Israeli Schools (12:05) IDF: “Nothing is Impossible” (13:55) Compulsory Military Service Contributes to the Success of the Startup Eco-System (19:03) Founding a Start Up in Israel (23:15) The Big StartUp Hubs in Israel (25:16) StartUp Life in Tel Aviv (28:00) StartUp Life in Palo Alto & Stanford (30:52) The Role of Silicon Valley in Entrepreneurship and Venture Capital (33:52) Fundraising in the United States from 2000 to 2022 (40:00) The 3 Success Secrets to Fundraising in the United States (56:00) Search Strategies During Fundraising in 2022 - signal.nfx.com (01:01:00) Recommendations when pitching US Investors (01:07:52) Pangea’s Solution in Precision Oncology (01:15:44) The Enlight Technology (01:20:30) How Pangea Helps to Find the Right Patient Population for Clinical Trials in Oncology (01:25:00) Pangea’s Collaboration Network (01:34:00) Enlight - Matchmaking between Patient and the right drugs (01:36:00) Pangea’s Business Model (01:40:00) Pangea’s Development Team (01:42:20) What is the next development step? (01:44:58) Advice to first-time founders Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Christian SoschnerThis episode is all about fundraising in Israel and the United States, precision oncology, machine learning, and deep RNA analysis. In this episode, I have a conversation with Tubik Becker. He is the CEO of Panchea Biomed and has started, developed, and exited companies in the United States and Israel. Now he is developing Panchae Biomed to start the next revolution in precision oncology.
Christian SoschnerNothing is impossible.
Tuvik BekerBut I think another very important factor is the way this area welcomes immigration and many US investors would only invest in US companies. Thought and emphasis is especially by uh budding entrepreneurs is having a wide funnel. You really have to start with talking to many, many, many. Do be mentally ready to to uh to have uh a hundred or more uh meetings in order to get this uh uh one uh initial checkpoint.
Tuvik BekerAnd Panjia's whole approach um focuses on harnessing these expression abnormalities in order to attack cancer cells and spare uh normal, healthy uh cells. So and light is able to create biomarkers for completely novel drugs or for drugs that uh are already um that already exist but have only been tried on a handful of patients so far.
Christian SoschnerTubik Bekka is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last 20 years building, scaling, and leading companies in the healthcare, financial, and aerospace domains. Prior to his role with Panchair, he co-founded Metware Limited and now serves as its executive chairman. Tubik holds a Bachelor of Science in Mathematics from Tel Aviv University and a PhD in computational neuroscience from the Hebrew University.
Christian SoschnerHe is also a member of 8400 The Health Network. Founded in 2018, Banja Biomed is an Israeli biotech startup redefining cancer care. The company developed Enlighten, the world's most advanced multi-cancer multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world.
Christian SoschnerPanchea aims to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to treat patients with success. Panchea is backed by NFX, and its technology has been published in leading journals, including CEL, Science Advances, Cancer Cell, and Nature Communications. In this episode, we talk about the startup ecosystem in Israel, fundraising in the United States from 2000 to 2022, three success secrets to fundraising in the United States, and shared in light technology and precision oncology.
Christian SoschnerEnjoy the show. It would be a pity that uh if we find out after the conversation that they have no footage.
Tuvik BekerSo we'll do it again, no problem. It will be interesting to to compare.
Christian SoschnerOh yeah, oh yeah, this would be interesting. Uh it's good to see you, Tuvik. Uh, do you do I spell your name right, Tuvik Becker?
Tuvik BekerTuvik Becker, yeah, that's that's uh right. Spelling and right pronunciation. Thanks, Christian. It's it's uh really great to be here with you. Thanks for the opportunity.
Christian SoschnerIt's good to have you here. Um I heard from your company in San Diego at the bio. And um initially I thought you are US-based. I had a look on your at your website and it's uh Bangea Biomed. And there is maybe I can put it up and can can show you directly. Uh, here's the share screen option. So I was on your website and it's really well done. It's this great website. I like the structure. I mean, it looks to me like you put the entire pitch deck on the website in a very logical and well-designed structure.
Christian SoschnerAnd when it scrolls down, um, I saw Massachusetts General Hospital, USC, University of Southern California, uh, National Cancer Institute, MD Anderson. And the first thought I had in my mind is was that you are US-based. Uh but you aren't. Where are you currently?
Tuvik BekerSo currently I'm I'm in uh Tel Aviv and and uh Punjia is based in in Israel. It was uh founded in Israel, and uh it's true that a lot of our activity is actually in the US and and hopefully in the near future in Europe as well, because uh uh we definitely are looking for collaborations uh in Europe. Uh there's a lot of activity in our space uh uh in uh in Europe.
Christian SoschnerSo I I misspelled the name of your company, obviously. Uh it's Pangea or Pan Pangea.
Tuvik BekerWell, it depends. Um in English we call it Pangea, in Hebrew it's Pangea, but uh Pangea is uh is perfect.
Christian SoschnerHow did you come up with the name of your company?
Tuvik BekerUm well that that's uh you know Pangea is the uh primordial uh all-encompassing uh continent. It had something to do with uh um the fact that that when we um try to find uh solutions for cancer, when we try to um to um find vulnerabilities uh for tumors, we have to uh adopt a holistic approach. So we look for uh terms that that would be uh something uh holistic and all-encompassing.
Tuvik BekerAnd Tangia sounded right. So uh we we liked it.
Christian SoschnerThat's that's a great thing. Um you started your company in Israel, not in the United States. Um when I look at Israel uh from uh from the countryside, I think Israel has about 10 million inhabitants, but correct me if I'm wrong. So it's a similar size than like for example, Switzerland uh or Hungary or Austria in Central Europe. Um but when you look at the ecosystem at the startup ecosystem, it's quite interesting because it looks to me it's of similar size, like uh Silicon Valley, for example, in the United States.
Christian SoschnerI see so many companies coming out of Israel. And the interesting thing for me to learn or to hear from you is why is that? What's your opinion? Why is Israel so strong in creating startups?
Tuvik BekerWell, it's it's a very good question. I think I'm by no means an expert on the topic. A lot has been uh written about it, and and uh there are people who have devoted their careers to studying uh this phenomenon and and uh really analyzing it. Um and um, but I can I can give my uh very uh personal perspective on why uh Israel is such a successful uh startup um startup community. And and I think some of it has to do with the pretty deep cultural traits in in Israeli uh society.
Tuvik BekerSo one thing um I think which which is uh uh quite fundamental uh in in Israeli behavior and and uh education, etc., is contrarianism. And and it has very deep roots uh even in the religious uh thinking and the way um the the Bible is taught and and um interpretations of of the Bible uh are taught, uh there's a deep trend of argumentation.
Tuvik BekerSo you have to present opposing views and argue the question rather than accept a doctrine. And and I think this uh goes on to these days, and and Israeli schools are um pretty unruly places where you're not supposed to accept what the teacher uh is telling you, but rather to be critical, to raise questions, to engage in a discussion. And I think this is really essential uh for um any startup because there are so many unknowns.
Tuvik BekerYou have to be very uh skeptical, you have to be uh asking questions all the time and and checking yourself uh because what was true yesterday may not uh be true today any longer. So I think this is one one thing which is uh very helpful for uh yeah.
Christian SoschnerIs it is it is it really that way that uh the kids in school are uh welcomed and invited to challenge the views of the teachers? Did uh did you understand it right?
Tuvik BekerYes, you did. It it is uh well it it can turn the classroom into a rather unruly place at times, uh but uh but yeah, it's it's uh at least in uh in the good schools, it it definitely is um a welcome attitude, and and uh uh there's a lot of um uh teaching of critical thinking and and debating, etc.
Christian SoschnerAnd the teacher doesn't have a possibility to cancel the kids to just say so you're out, you're out, you're out.
Tuvik BekerSo the possibility exists, but but uh it's uh reserved for for extreme situations, of course. It's not you know, just because you uh you raise an opposing view, that would probably not happen if you're doing it, you know, if you're disturbing the class, that's something else. But if you're just saying, well, it seems to me that uh there's another explanation, for example, or I heard an opposing view, uh that this is definitely welcome.
Christian SoschnerSo the kids have to learn in school then very early to uh bring up their own point of view, but also uh to back their point of view with evidence. So it's not just that they can say, okay, teacher, you are wrong. Uh I have the right opinion. So they also need to learn then uh to do proper research, uh, to find material and to discuss on a more adult level. Is that the right perception?
Tuvik BekerYeah, I I think that you know that that is definitely the ideal, it's not always real life, but in terms of of uh the culture, it's it's definitely there. And um, you know, arguing is is very natural uh for for Israelis. Um another thing which is uh quite deeply uh imbued in in Israel is is uh uh the feeling that nothing is impossible. Okay, and and um uh in the IDF in in the Israeli military, uh this is a very, very strong um uh uh trait or or uh notion that that uh is being taught.
Tuvik BekerUm and uh as you know that there are uh there are many elite uh technological units, and this uh really applies very strongly there. So often young uh soldiers who've just come out of uh of high school, uh very talented, are faced with extreme challenges, extreme technological uh challenges. Not only that, of course, uh you have the um uh physical challenges, you have other ones, but uh um I think it's it's especially interesting that um young people are faced with uh uh really demanding uh challenges, and the notion is there's no such thing as impossible.
Tuvik BekerYou can do it, find a way to do it. And uh with with Team Spirit, um uh you can often overcome things that uh uh would uh would otherwise seem uh impossible. And I've I've personally seen that happen many, many times. That uh you know if you don't uh know or if you don't think, if you don't come with the superstition or with the presupposition that something is impossible, it is in fact uh uh doable.
Tuvik BekerUh and uh it even happened to me uh in the past that uh that that's uh separate story. Um and um I think that the third uh factor that comes into this uh success as a startup community also has to do to some extent with the um compulsory uh military service, and it's the fact that um the army brings together people from uh all of Israel from from different backgrounds, different socioeconomic um backgrounds, and it creates situations where you have to work as teams, and uh this creates really closely knit uh social circles.
Tuvik BekerAnd um it is quite common uh in Israeli startups that you see a startup being established by a team from the army, and and it doesn't necessarily have to be a team um that work together in a technological unit. Oftentimes it's a combat team where after the army service, everyone went their own way and one became a marketing person and another became a technology expert, etc.
Tuvik BekerBut then when one of them has an idea, they come together as a team because they have this background, they know how to work together as a team, and and uh this often leads to uh pretty good uh startup teams. Uh so you know I'm not sure these are the three most important factors or uh that uh they explain a lot of the phenomenon, but but uh these are definitely observations that I had for uh why um Israeli startups are uh relatively common and uh relatively successful.
Christian SoschnerYeah, makes uh makes sense to me. It sounds very reasonable. I mean, the first one I would uh if I should give it a title, it would be the search for truth. So uh it's cool that to encourage kids to learn more and uh to always find out what's true and what's not true, which only can uh evolve through conversation. Um the second point was also great. Uh, the attitude in the army that nothing is impossible, so that you can achieve basically anything. I think it's very encouraging.
Christian SoschnerAnd I also agree to the third point that you made, the military service. Um, I think do I remember that right? It's I think it's two years in Israel, and it's uh every young Israeli has to uh join the army.
Tuvik BekerIt's actually three years. Three years? Oh yeah, it's that that's that's the minimum. For for women, it's it the minimum is two years, but uh uh it's often longer. So uh uh kids who want to go to any elite unit uh would would um normally subscribe for a longer uh term service. Uh they want to become officers, they would serve longer if they want to uh serve in a technological uh role, they would uh sometimes learn initially and then serve longer.
Tuvik BekerSo yeah, it's it's a it's a very significant uh uh period in in every uh uh young person's life in in Israel.
Christian SoschnerSo it's 36 months. I mean, my service in Austria was six months, so it was a little bit shorter. But uh I had a conversation recently with uh Tobia Silverzan from McKinsey. Uh we talked about uh habits and lifestyle habits that are important for entrepreneurs. And it reminded me of my time in the military. And what we were talking about, for example, was uh uh why we need sleep. So why sleep is so important uh for mental health and especially for entrepreneurs. Then um another thing we were talking about was uh discipline, habits uh or nutrition.
Christian SoschnerAnd it reminded me of my time in the army that uh these were basically the basic skills that were taught at the army during service. So to get up at 6 a.m. in the morning, uh, to follow um uh a certain plan throughout the day, to complete tasks and not uh leave tasks open, uh, to exercise, to train. And when you say that uh basically every Israeli has to uh attend 36 months the army, I think this is then just uh the basic lifestyle that people learn over three years.
Christian SoschnerUm, and maybe that also influences then the attitude in a startup. Would you see it similarly, or did you miss something?
Tuvik BekerNo, no, I I I definitely think so. It's uh it's really hard to overestimate the influence that uh the army service has on all aspects of uh um Israeli society, and and and these are definitely uh some some of the ways uh in which it does.
Christian SoschnerUm I'm curious about the next point. So uh there's a lot of training in Israel that basically uh fosters entrepreneurship thinking. Um, how is it to found a company in Israel? Can we maybe walk it through uh and take your company as an example? What are the steps that you need to take?
Tuvik BekerYeah, so um I'm you know, by now it's it's not my first or second or or even third company. So I'm not sure that would be the um the best example, but but going back uh into my first time uh as an entrepreneur, uh it's actually been something very natural. First of all, you see a lot of people around you who do that. So entrepreneurship is pretty common. Uh, many of your friends uh do that, uh, or or older people that you know um do that.
Tuvik BekerSo um uh I think that that um lowers the the bar for uh uh deciding to become an entrepreneur. Sometimes it it lowers it too much. So it seems uh less of no one really prepares you for how hard it it it really is uh to um not so much to start a company, that's the easy part, but uh to to have a thriving company, which is uh really something uh pretty hard.
Tuvik BekerUm but uh uh as I said, it's it's um relatively easy to come up with an idea and then gather a group of friends that would spend some time with you on this crazy idea of yours. And basically um uh right after the military service, so that's usually the age of uh 21, 22. Often people go on a long um um travel, uh okay, long tour around the world uh right after the military service.
Tuvik BekerSo early 20s uh is a time when when um many Israeli youngsters come up with some idea and then they gather some friends and let's start a company around that. And of course, then uh it's time to raise some money. So people go and and uh talk to investors, talk to angel investors, talk to um uh VCs. Often the first money comes from friends and family or small angel investors, and then if if the idea really uh holds water and and uh continues to develop, you need to seek more uh institutional investment, etc.
Tuvik BekerUm, so I don't think there's one path, there's one way to do it, uh, but it's just a pretty common thing to do, and and many people try it. Most try it once and and uh do not succeed and then move on to do other things. Uh but some uh really get uh hooked on on this uh um this lifestyle, this uh um uh direction and and do it over and over again.
Christian SoschnerI was smiling while you were talking, it reminded me of my my first try. the startup, but it was I mean not really a startup, it was a spin-out from Novartis, um, which was funded from the first day with PC money because um the the let's call it the founder of the department in Novartis was Rodger Novak who then later on founded CRISPR therapeutics. And when I talked with my friends here in Austria um when we all exchanged information what what we are doing professionally and I said uh I'm in a new company they said what why why throwing why are you throwing your your your life away why don't you go to the industry and work in a in a real company so it was 2006 so it was a long way back meanwhile the situation has changed and uh a lot of money from the government was invested to foster a startup ecosystem here in in Austria and I think Rihanna and life science has become a startup hub in Europe.
Christian SoschnerHow are how is the situation in Israel?
Tuvik BekerAre there similar hubs uh in Israel that uh or regions in Israel that are famous for um fostering the startup ecosystem sure there there are quite quite a few so Tel Aviv is is obviously the the uh the biggest and most dense uh startup hub there are uh hundreds of of uh uh successful startups and and probably uh thousands of of uh aspiring um startups uh in the Tel Aviv area alone um there are significant uh startup hubs uh in Jerusalem and also in the Galilee there's a lot of uh biotech uh and health tech uh going on uh in the Galilee in in Jochem in in Komiel small uh towns in in the northern part of Israel and also in the in the south in in the desert around uh uh Ben Gurion University in in Bersheba does uh a lot of uh activity so you know the uh I I would say that um every big university sprouts uh innovation and and around them you would find uh people with bright new ideas that uh want to translate that from basic science into technology into products into something that would make a difference in the world so uh uh you know it's not like there's one um one hub but uh it's it's really wherever there's uh there's a good university there there's also a lot of startup activity sounds like the whole country I'm always impressed um by the people by the entrepreneurs in Tel Aviv uh the pictures I saw from Tel Aviv remind me always of Barcelona so beautiful beach and uh great summer um great environment for not working so I'm always impressed that the entrepreneurs then basically sit down I would rather go to the desert so it's basically when I want to work get something done how is life in Tel Aviv well I I really love uh Tel Aviv I spent uh around seven years in in uh in the US uh first in uh in California in Palo Alto Stanford and then in the Midwest and and I love both places uh a lot but um coming back to Tel Aviv uh was was uh really wonderful because I think the combination of a true city that that's alive uh 24 hours a day uh seven days a week uh so a big metropolitan area with a nice warm sea it's uh it's quite unique that uh you you you don't find uh uh that that combination in in many places and uh for for people who uh grew up uh close to the sea I think it's it's hard uh to live uh very far away from it or uh also I I found it hard to be in uh northern California and be so close to the sea but still not be able to to swim uh or to enjoy swimming anyway because the sea is too cold so I think it's uh um it's kind of uh an ideal combination in that respect not in other respects i i don't like uh the weather in in israel in the summer except for the sea so it's it's hot it's humid in in uh in the tel Aviv area but you know you can't have it all so uh overall I think uh quality of life in in Tel Aviv is is really high so lots of culture a lot of excellent food uh a lot of fun uh and uh and of course uh many many uh uh good options for for doing great work so uh uh the talent pool is uh really uh wonderful it's uh next to none uh in the world from from my own experience I think if I was in Tel Aviv I would probably do all my meetings at the beach so having coffee it's in fact different we do that we do that pretty often so uh there are many meetings uh at the beach in in cafes if if you see the cafes in Tel Aviv it looks like no one ever works because they're always uh full and uh when what are all these people doing here why are they not in the office working but yeah that there's a lot of uh there's a lot of work going on uh in cafes and and on the beach and in the parks etc so yeah it's uh it's a lively and lovely environment I think you mentioned before that you spent seven years at Stanford in Palo Alto uh how is life in Palo Alto in California I spent I spent three three and something years in in Palo Alto and then another three and a half years in uh in the Midwest and as I said I love both places life in life in Palo Alto is uh um is unique so first of all I think Palo Alto has the perfect weather i i uh never uh was in a place with uh better weather than than uh Palo Alto it has this uh um um magical micro climate uh that that's uh always nice almost um but of course it um with with Stanford and with Berkeley across the bay uh it's an amazing place uh for for good science and and uh and it's an amazing place for entrepreneurship and uh in terms of funding opportunities uh uh israel can can only dream of of uh uh the funding opportunities that are available um in uh silicon valley so you can do everything bigger and faster um on the other hand that the um uh competition uh for talent is very fierce and and uh cost of living is very high etc so you know it's always uh it's always a balance but uh i would definitely recommend uh to to any entrepreneur to spend some time in in silicon valley or in palo alto is one of the uh best places probably uh to to understand the way it's done there because uh that there's a lot to learn from it let me ask you one question about uh palo alto uh your opinion um i mean we have an entire planet with many countries many cultures many cities many universities but uh the area around Stanford seems to stand out in entrepreneurship globally so I think there is nothing comparable to to Silicon Valley and when I was a student was in the 90s in Austria I think it always looks to me uh that Europe is at par with the United States so back in the 90s 80s 70s when we look at invention and uh entrepreneurship and development also of uh larger corporations I think back then also a lot of inventions came from europe mobile for example mobile industry uh europe played an important part in that and then suddenly it changed I mean I think with with uh in the 2000s early 2000s silicon valley simply took off and uh no region in my opinion uh can it's comparable to silicon valley do you have a theory why that happened um what's your opinion on that well i i think um again i am no expert and only giving my my personal uh opinions but uh one one thing which is quite obvious is is just the amount of money uh that's uh that's available that that's seeking uh novel breakthrough ideas to to uh to back um but i think another very important factor is the way uh this area welcomes uh immigration and and uh and foreign innovation uh i felt it personally when when i was a foreigner um in in silicon valley and um i i came uh to california in uh 2002 this was after the uh dot-com bubble burst and it was still very very hard to raise money at that time uh and yet we were uh we were able to do that we were quite uh uh persistent in our attempts we met with lots and lots of uh uh investors until we we uh found one it was uh labrador ventures and and uh i would always cherish their um welcoming uh approach and um uh and it was it was nice to be clearly a foreigner and yet uh uh accepted and and uh and trusted uh so i think this openness uh to innovation um uh by foreigners uh by people who who come from other countries is is important because uh many studies who who uh looked at the sources of innovation a lot of it is coming uh from um immigrants uh i think that this is one of of uh uh the contributing factors and and uh um i believe that uh silicon valley is quite unique in in this respect i couldn't agree more i mean um don't know very well the situation in the united states but in europe um looking at life science um after series a would say it's it's really tough and challenging to raise large amounts here in europe so the usual way for european companies is simply to sell sell uh everything to industrial partners and start from scratch um i don't think that there is anything comparable to the US capital market uh uh in Europe or anywhere in the world um I'm curious is that uh you tried the first time to raise funds uh in the United States in 2002 so right after the dot com bubble burst um let's dig a little bit deeper into fundraising in the United States uh how was it for you in 2002 uh to to to go where no man went before after the dot com bubble burst well it it was very hard uh it it uh it took a lot of uh um determination and and uh pretty thick skin uh to uh get lots and lots of rejections um before someone um uh decided to to take the risk and and uh uh back us and and invest in um what we did um and and it was um a tremendous learning experience not just uh fundraising of course but uh the the whole experience of uh um that first company it uh really taught me a lot and and shaped uh everything I've done uh since then uh to an extent so uh as I said it it's uh uh I think it's it's a period that that's uh uh very beneficial and and I would definitely recommend uh spending some time there um I believe that many European companies want to raise funds in the United States um could you could you give uh a walkthrough uh what you recommend how they should approach the US market or is it just get a ticket uh to San Francisco uh and then go into the next bar and you will find all the investors there or no I don't think so I don't think that's the way it is first of all I I think it's hard for foreign companies uh which is different from foreign entrepreneurs hard for foreign companies to raise uh money in Silicon Valley so many US investors would only invest in US companies so uh you you uh my my company back in 2002 it was a US company it was started in Silicon Valley and and it raised uh local money although uh the entrepreneurs were foreign uh so um going uh to the to the US to raise money uh for a European company or for an Israeli company for that matter um is much trickier uh than than relocating to the US for a few years starting a company there and uh and uh raising money of course this is more difficult from different aspects and not not everyone is is willing to to relocate but in terms of uh uh raising uh the money it's um it's much much easier to do it for for a local company and and some investors are really extreme uh in that sense they only invest within their metropolitan area so I've heard from several investors who said um I'm not investing in any company where I cannot go into my car and visit their offices within 20 minutes.
Tuvik BekerSo uh really um uh restrictive and and many investors like to um to really have that immediacy of of uh uh contact with uh with the companies that they invest in um I think in in Israel uh it's somewhere in between because many of the uh big VCs have branches in Israel that are making investments uh in in uh the Israeli ecosystem and and and this could probably be replicated uh in europe and and I'm sure it is I I just don't know enough about the uh vc ecosystem in Europe but but I'm sure that that uh from from the little I know um you have that as well um so uh that that is that is of course uh one way of doing that um I'm not so sure you said that the BQCs in the United States have branches in Israel so they have their offices and they invest directly also in Israel yes that they do so sometimes uh sometimes it's a really separate uh um entity with their own mandate sometimes uh uh it's just partners that that are uh local to Israel and and the decisions are made together uh at an investment committee uh in the US it really depends there are um several different models but uh uh many US VCs have realized that there's a lot of innovation going on in Israel and it would be good to uh diversify investments and and have local teams here so uh that's one way of of uh getting to to US money uh um in Israel it it's still it's not exactly the same so if you look at valuations um in Israel and and in the US there is still a gap so the same uh VC uh you can see a gap in in the um valuations given to uh Israeli companies versus ones in the US and and there's also logic beyond behind that because um go to market is different when when you're away so uh uh that there are many factors who would uh affect that but uh it it's definitely uh a good way to to uh allow money to to flow more globally oh definitely I didn't hear something like that from from other european hubs but uh maybe I missed also something I would say comparable probably is uh United Kingdom London uh area but in Austria I'm not aware of uh uh of usbcs having uh having their offices in Austria uh we would be very happy um when when I look at uh fundraising in the United States uh could what what you learned in the last 20 years could you sum it up into three success secrets uh frankly no uh no i i don't think i could i could sum it up uh into uh success secrets but but i can i can you know uh i can probably uh give some some points which i found important uh the first point which is uh i think it's it's uh uh it's trivial and it's a cliche and yet it's often not given sufficient um uh thought and emphasis especially by by uh budding entrepreneurs is having a wide funnel you really have to start with talking to many many many investors if you want to um eventually uh succeed in in raising money you have to meet lots and lots of people most people wouldn't invest in your idea even if it's perfect even if it's the best idea in the world um you know for many different reasons and and uh you know the big uh uh the big funds have their anti-portfolios all the investment opportunities that that they missed and and uh some of them are are famous for um publicizing that uh so it doesn't mean your idea is bad if you get many rejections can can we state the funn level a little bit uh very often when I speak with um founders here in Europe uh it looks to me uh from the expectation side looks to me like uh they expect to have five meetings and get uh the investments done when you say you have to talk with many many many uh with these many many investors until you get one um to invest in your company uh can we nail it down with a number how many conversations do you think you need to have to get one investor is it uh five conversations or is ten conversations yeah okay so so that's not the right order of magnitude so I think uh if it's your first time as an entrepreneur be prepared to talk to over 100 investors before you get an investment and and uh with uh with my first company um our roster of of uh investors that we actually met with uh we had more than 120 uh meetings before we got an investment so it's true these were really uh tough times but then again right now we are also uh in in uh uh a bit of of uh rough times we uh are uh in something that does look like a a downturn after two uh quite uh spectacular uh years for for entrepreneurship and for um uh vc funding um so yeah um if it's your first time if you don't know personally many investors if if you don't yet have a reputation as someone who's done um uh this course successfully in the past you would need to to meet with many many many investors to secure uh funding later on you can of course uh uh get it more quickly and and uh uh and with less effort and and of course there are those uh super successful entrepreneurs that when when they only start a new company investors are are fighting for uh the chance to invest in their uh new business but uh that uh uh that's a very select uh elite I completely agree after building your first Tesla probably it's not very difficult uh to raise money when Elon Musk goes on the market and say to another company uh
Christian Soschnerprobably it's uh difficult. I completely agree with what you say. So we have the first success secret.
Tuvik BekerWe uh expect uh to get a lot of rejection and speak to to many VCs and don't give up and uh would say when we put the number on it uh expect more than hundred first meetings to get one investment yeah i i i would say that that's a good rule of thumb um hopefully you'd get it earlier but but do be mentally ready to to uh to have uh a hundred or more uh meetings in order to get this uh uh one uh initial check by the way once you have a lead it's often much easier to get follow-on investors so uh uh there are many who would like your idea but wouldn't have the confidence to set terms for for uh um for a round because they don't feel they have sufficient expertise but if someone else with more expertise in the field would come in and and uh set terms then they would be willing to to join so uh really focus on lead investors meet with others always build the funnel for uh fall on investment but uh but focus on the leads and and I think that the second thing you you have to um keep in mind is prepare for the meetings and know what the investors that you're going to meet are looking for okay so it's uh it's very very important to understand where they're coming uh from what's their investment philosophy what uh they are looking to invest in and see if there's a fit if there's no fit a priori maybe it's a waste of their time and and a waste of your time so try to concentrate on on um investors who really are interested in in what you're doing and then try to have good answers uh to uh to meet their areas of interest so so i think that's um that's the second thing and and um if you press me for a third absolutely okay so um i i would say that uh at least for me personally it's it's been important uh to not be afraid and and admit what's still unknown okay because uh startup companies is uh i i always uh think about it as uh um as a ship sailing in uncharted territory and and drawing the map as it goes so you have a new idea and and if it's really a um uh an idea with uh at least uh uh um a grain of of uh of true novelty there will be questions which have not yet been answered and you'll have to ask the right questions and and find the answers as you go so you have to strike a a good balance on one hand you have to convince your investors that you have a clear path forward okay you have thought out well the details of what you're going to do in the next 12 to 24 months let's say and what's your offering is going to look like etc and how you're going to um uh pass certain hurdles which are uh sure to be on your way in the uh short to midterm but then again it's only natural that there would be questions to which you do not yet have the answers that's just the nature of of of the beast and and I think it's important to admit that to to admit your um limitations in terms of what you still don't know because if you can ask the right questions if you can uh draw the map and and also say here I have a blank area I don't yet know we'll have to get good answers to these two three questions within six months because these are important for our next steps.
Tuvik BekerBut right now we just don't know okay that's I think that's a very um very credible approach and and uh it instills more confidence to come up with this approach than try to pretend that you know everything in advance because that just uh usually it's not true and and it leads to catastrophes if you if you try to stick to your theory uh when you still don't have sufficient information uh that's not a good uh recipe for success so um know enough to to move forward but but don't be afraid to to admit what you still don't know yeah I think there was a big example recently in also I think in in California I forgot the name it was in diagnostics um was uh a huge blow up um tyrannos it was terror oh yeah not not so recent any any longer but yeah of course uh teranos was uh an infamous example which which has um tainted the whole industry for for um for a long time and I think we're we're still uh recovering from uh from the effects of of uh that ordeal and I think this um showing that there are gaps and that there are things that the team don't know is also the reason for VCs to invest in the company in the first place.
Christian SoschnerSo if everything is already sorted out uh especially in life science um why should the VC then invest in a company so it's uh except it's kept scaling but we're talking now about pre seed seed series and as far as I know from my European experience is VCs invest in that company to help the company get to the next step and create data along the way so this is their investment plan. So I think it's uh it's a great approach that you recommend uh being open with the reality yeah and in in general I think uh in building a relationship with your investors with your board with with everyone any stakeholder in in the company um sincerity is is is uh really top importance uh it's uh the the one most important thing uh to bear in mind you must be uh absolutely frank and open and and if there are difficulties uh you have to to convey them clearly of course uh you know in and um chart a way forward uh say how you're going to overcome the difficulties but but never try to hide uh the difficulties because uh that that's uh that's really a recipe for disaster what matters to me most in businesses are relationships basically and I think lying uh is something that definitely harms a relationship and makes it more difficult to engage in uh in anything in future um how do you rate uh relationships um what's your experience with building relationships during fundraising uh do they matter or are they not so important is it more transactional no I I think uh it's the most important I I totally agree with you I think it's the most important thing not only with um uh with uh investors it's also internally in terms of uh team building I think the most important uh um thing to do is is build a team uh which is cohesive which uh has strong relationships where people really try to help each other rather than compete with it each other internally because um it's very very hard to succeed as a startup competition is extremely fierce and um and um things are very dynamic so you might be on a roll um uh one day and and two months later you're uh really in in deep trouble something comes up and and you have challenges uh uh you didn't even dream about etc and and you have to be able to uh survive those ups and downs and uh they all take a psychological uh toll um so it's extremely important to build a strong team and this is true um for for uh uh the employees for everyone in the company and and it's true uh also for the relationship with the board and with the investors so it's important that everyone is together we are all in the same boat and we are transparent and uh we are in it together and your investors really want you to succeed once they they wrote the check they're with you there the uh and it's extremely important to align interests with your investors so think about it uh all the time you want to have the same interests between um founders employees investors all have to be aligned and and working towards a common goal of course easier said than done there are um forces that would always create some some uh some misalignment some conflicts of of interest but these should be um minimized to to to be uh as much as possible that's true aligning interests I think is also very important I had uh in in recording three weeks ago uh the podcast is already live with Donna Lavoe she consults um life science entrepreneurs in how they should present their company to investors and uh to industrial partners and she showed the vertex pharma pitch deck from the early days and the title page and uh there was the clear statement we want to build a pharma company so we want to make something big and I know from Europe for example the RVCs on the market who don't want that they just want uh to invest in a single asset company move it one step forward and then sell the technology very quickly to the pharma industry and when the entrepreneurs and the founders don't address that early on uh they risk ending up in a situation where one side wants to build something similar to vertex and on the other hand uh maybe they find investors who don't want that and then it becomes really tricky to move that forward.
Tuvik BekerRight right and and I think it's it's really hard to resist the temptation to tell investors what they want to hear. Because uh sometimes you you meet an investor and you have your plan you want to build your big company and uh they seem to want something that would uh sell quickly and and I think um you have to make that tough choice either you convince them to go with your vision or you're willing to forego your ambitions and and go with what they want but it it just usually won't work if if you take their money and and you hold on to what you wish to do which is contrary to their goals and incentives that would lead to to strong misalignment and and and it there would be trouble down the way and and it's better to avoid it uh uh from the beginning and just try to find investors that you will be aligned with and and uh because otherwise you are funding your company but but you're priming it for failure down the road so why waste those next two years just to meet frustration uh when when when it's um uh if and when you are successful that that's really a shame so spend another three months or or five months on finding investors that that you are aligned with or just face reality and and change your expectations to to match those of of your investors but uh um if you can be okay with that no i couldn't agree more i think especially when it comes to values and beliefs also from the entrepreneur side i mean if it's really a calling uh in an entrepreneur like jeff bezos for example with amazon to to to to at least try to give it a shot to try to build something big uh i i doubt that it's so easy to change without significant failure in between so to just give it up and say okay now I switch if it's something um that's not a value for example okay I don't want to I don't want to move to San Francisco maybe it can be overcome so move to San Francisco why not I mean you get money there it's uh it's no problem and when you don't find one in Vienna also with DVCs I think when they have uh they have it encoded in their DNA already that they just don't fund IPOs so that they want to sell it it's also very difficult to change that or to make them change so putting that on the table early on I think this is the success secret probably number one of uh of um um early stage companies seed stage companies aligning the interests of the early team is extremely important right so so you know I I I I totally agree and it's um it's important to to um to remind entrepreneurs that you don't need all the investors to agree with you you need to find one that uh really um transmits on on the same wavelength as you do okay you have to find the right partner for your company but it's so much easier said than done uh because after you you've met with um 50 vcs and and heard no 50 times and then the 51st tells you yes but I have these conditions and these conditions don't really align with with your beliefs it's very very hard not to be tempted to say okay we'll we'll do that that's that's fine and just ignore uh the fundamental difference in what you want the company to look like uh three years from now or five years from now and what they do so it's uh it's much easier said than done but I think it's a uh it's a very important point to to bear in mind when when going to raise money for your new company I agree to what you say when we're talking when we are talking about raising money um 2000 2006 uh were different times technology wise and you recently uh raised the seed round with your company um what search strategy do you recommend to founders early stage entrepreneurs these days i mean the technology level has advanced tremendously in the last two decades so we have uh lot uh going on on linkedin um on the internet uh what is your approach when you uh try to build your funnel how do you approach uh searching for vcs these days okay so so nowadays I think it's it's much easier uh so you have uh resources like uh uh pitchbook and and others that uh um provide information on on a lot of vcs one tool that uh I find extremely helpful uh is actually a tool by nfx uh which is called signal and and it's um it's open to to the whole uh community I think the address is signal.nfx.com or something like that but if you google signal and and and nfx you you'll find it and um it connects entrepreneurs with uh investors and it has a a very extensive um roster of uh investors uh and many parameters about them so you can look up which areas they've invested in before you can look up uh the range of of uh um uh checks that that they write what's their sweet spot in terms of uh ticket size uh what stages they invest in so you can really run searches that uh uh come up with investors who are um most suitable for what you're currently looking for and and uh uh in in uh building the um lead uh list for for uh our seed round i uh heavily relied on uh on signal for uh building that and in and it's been uh very useful another thing it also shows you um it has this kind of uh social network uh feature built in so you connect with people you already know whether it's investors or other entrepreneurs other people which are um which have signal accounts and it shows you what's the introduction patterns that you can get to certain investors so if you know someone who knows that investor you can ask for an introduction so I I think it's um somewhat like uh LinkedIn but um specifically useful for investments and and uh has many features that uh that are very very helpful in general nfx has uh invested a lot in creating tools for um the startup community that they rely heavily on um on technology and and they're doing a great job in uh creating uh tools many of them are are internal for uh the nfx uh portfolio uh companies but uh signal is a good example yeah that's it that's a that's a great point uh i was not aware of that it's uh there is i think a similar app with a similar name on the market but it's not it's different uh it's not signal app is uh which is comparable to whatsapp so it's uh from nfx ventures yeah that that's uh that's something something else yeah signal as a name used so a lot but and this one is uh dedicated to Israel New York City Los Angeles Seattle San Francisco yeah I I think it's it's pretty global but uh but it's uh uh you have London there and and you have Canada etc but of course uh there's uh overrepresentation probably for for uh uh us and and uh some um there might be some overrepresentation for Israel because NFX does have uh offices in Israel of course as well as uh uh the US the European uh the uh European Union citizen in we would say it cannot be international because there is nothing from uh the European Union in there so it may be a it's maybe a reason also for our European VCs to reach out to NFX and uh signal and to come yeah definitely I I I'm sure I'm sure it can be uh extended to include many more European VCs.
Christian SoschnerI just imagine that uh when someone then hears the episode listens to the episode and uh finds the NTSEP and wants to reach out to VCs uh works through two or three hundred uh investors from the United States and then comes the big day um the first one agrees to a meeting in person to board a plane fly over to somewhere in the United States and then the question that pops up in my mind is uh are there any cultural differences that you see between uh the world in Europe Asia so when we look at the Mediterranean area for example compared to the US area is there anything that you recommend to founders who reach out to US based investors uh to have in mind when they start with their presentation and when they start engaging with US based investors are there any cultural specific specialities yeah that there probably are but again um I I wouldn't consider myself an expert on on uh cultural differences i i would generally from what you experienced yeah yeah no sure i i would generally recommend um trying to be yourself okay so uh uh try to be comfortable with the with the situation and uh uh you know uh dress uh reasonably don't overdress not don't underdress like i did today uh um but uh um just uh become ready to to really have an open discussion of what you're presenting so plan on on leaving time for uh uh discussion and and uh um you know i'm i'm i think at least in the in the us uh they're very used to people from all over the world so don't think too much about uh uh cultural differences i think it's different uh in asia uh but but it's also it's it's beginning to change i've i've raised money in in um uh mainland china and and hong kong and and you see more of a uh global approach now i'm hearing that japan is still uh much uh more conservative and and sticks to the uh their um uh habits etc but i've never raised uh money there and um with europe again it's uh we we are all a a global village now so um meeting with investors in in asia and us of course israel and and and in uh europe i didn't find something that struck me as really a crucial uh cultural difference that that uh should be a major consideration just uh concentrate on on on the business on the vision and and on being open uh for for new ideas and and discussions yeah i hope it stays that way that uh we are a global village uh and don't go the another in another direction it's really great to see how the cultures merge together in the last uh one and a half decades when um i look at your website let's go to your company um what is the big problem that your company wants to solve so so pungia um uh does the precision oncology and precision oncology is is really a uh a fascinating area and as as you as you know uh there has been a tremendous uh revolution in in oncology over the last 20 years so 20 years ago uh if someone had a non-receptable uh cancer so cancer that cannot be just removed uh completely uh through operation if if it progressed beyond that stage it was basically a death sentence so you would be fighting for time but uh there was no way to cure people of of cancer unless you caught it very very early and then uh either removed it surgically or or managed to uh ablate it with uh radiation or something like that beyond a certain stage it it was hopeless and over the last 20 years uh there's been a revolution with um targeted therapies therapies that target specific vulnerabilities that are unique to cancer cells and and do not occur in in healthy tissues and they uh these are our novel generations of um of of therapies beyond the the traditional chemotherapies um which are sometimes much much more effective and beginning around 20 years ago we've seen cases of people with advanced cancer where um therapy uh actually leads to complete elimination of the disease for prolonged periods of time it may reoccur but um but uh you can actually uh get complete remission uh just by using drugs and this is of course amazing uh but but if we look at at the the situation nowadays 20 years after these uh uh first miracles uh began to happen um it's still applicable to only a very small um fraction of the cancer patient population right so uh the current dogma for precision oncology and for targeted therapies relies on finding specific uh actionable mutations sometimes it's different kinds of of uh genetic events like fusions or or uh translocations but uh let's use the the term um mutations uh um and uh if a patient is lucky enough to have one of these mutations in his or her tumor then we can match a particular drug that targets uh this uh this mutation this vulnerability of the tumor and sometimes it's uh it's very effective but there are two problems with this approach the first is that these actionable mutations are actually pretty rare so in around um eight to nine out of every 10 patients you wouldn't find any actionable mutations you would find many mutations but most of them are uh variants with unknown uh clinical significance okay so we don't know what to do with them we know that they occur but we have nothing to to offer these patients and the other problem is even if you're lucky enough to have one of these actionable mutations found it's not as if they are perfect biomarkers so if you'll get a drug matched based on uh such a mutation it will only work in some patients 30 to 40 percent of the patients so the bottom line is that um only five six maybe seven percent of the whole patient population actually benefit from all these wonderful uh new drugs um that have been developed in the last 20 years and and this gap is is is a huge gap because we found ways to um to treat cancer effectively using drugs but we only uh we are only able to do that for um a small fraction of the patient population and the question is how do we bring it to the vast majority of the patients and Panjia's approach to to that question is is is quite unique so instead of looking at the DNA and and looking for um the defects in the genetic code what we're doing is looking elsewhere we are looking not at the code but at the way this code is actually translated into uh proteins in the cell because when one examines cancer cells you discover that although cancer is really characterized by mutations by by uh genetic aberrations the most remarkable characteristic of cancer cells is actually expression abnormalities so in every cancer cell you find hundreds and and even thousands of genes that are normally coded so there's no defect in the code the the DNA is is uh intact but they are abnormally expressed they are either very significantly overexpressed or very significantly underexpressed and Pangea's whole approach um focuses on harnessing these expression abnormalities in order to attack cancer cells and spare uh normal healthy uh cells okay so that's that's the basic premise and based on that we we manage to develop tools uh both for improvement of um the drug development process so uh develop more effective drugs more quickly more accurately and for matching both existing and novel drugs to the patients in in uh a more accurate manner so finding the best drug for uh each patient in a highly personalized manner so that that's the the story in a nutshell that's the problem and that's the direction for solution how how high is uh your success rate then in in finding the right patients for the right treatment you mentioned before that uh with this new personalized medicine that appeared two decades ago uh only a very very small fraction a very narrow fraction of patients qualified for that when companies work with your solutions uh do you have a number uh how much bigger the the how should I call it uh the success rate than is of finding patients yeah sure so you know that the um um the challenge here is is uh measuring it properly and and uh finding uh sufficient data to to accurately estimate um what we've done and this has been published uh in in top journals like uh cell and uh um uh nature etc is we looked at retrospective data of uh yeah um uh of uh patients who received targeted therapies where there was follow-up and we knew uh first of all which therapy the patient received we knew did they respond to the therapy or not and we also knew the molecular characteristics so the DNA and RNA sequencing based on which we compute our enlighten matching score enlightened the name of our our platform and the enlighten matching score is a score that measures to which extent a particular drug um is expected to be uh efficacious for a very particular uh tumor so all in all we've done that on around uh um uh 1500 uh patients from from uh couple of dozen um uh uh different clinical trials where we had this uh retrospective data and and uh what we see is is the following and then that's from many different cancer types and many different drugs uh that the uh these patients uh have received so first of all for over uh 85 90 percent of the patients and light um does find uh some drugs with a high and light matching score so it almost always finds a matched therapy for a patient in the vast majority of the cases and for patients who actually received uh an enlightened matched uh drug um the uh response rates were significantly higher uh than the baseline in those clinical trials so um we we published that uh uh last year in in cell and and there this year there's been uh um publication in in uh bioarchive which is hopefully going to be uh published in the uh top line journal in the next couple of months that that shows uh that these results hold on a very uh wide range of of uh therapies and um cancer types so altogether it leads to a several fold increase in the number of patients that can benefit from existing therapies so that's the personalized medicine angle thing but there's also the ability to find the the right patient populations for novel drugs that are being developed and that these are collaborations that we are engaged in with pharma companies and and biotech companies it's a great opportunity for me to challenge what I learned about cancer research in the last uh years uh I remember that uh to what you said I remember it was I think a conversation from a couple of years ago where someone said that 99% of all drug development in cancer fails in clinics so it's uh a very very high failure rate compared to other indications and one of the reasons um was um or is the least that uh when the research the RT companies and teams don't find the right patients then a probably effective and safe drug relatively safe drug when we talk about cancer uh fails in clinics which could have benefited other patients so it's really uh a huge problem in the pharma industry to find the right patient population and when I get you right it's this is the problem that you addressed when we look at uh companies who are doing RED in cancer did I understand you right yeah yeah you understood uh perfectly right so I'm I'm not sure about the uh the exact numbers but uh uh definitely most um uh novel oncology clinical trials fail and they usually fail uh relatively late so in in uh stages two and three and and this is indeed a huge cost uh burden and and uh and you you're correct that they mostly fail not because the drug doesn't do what it's supposed to do it does however um it's hard to predict which would be the exact patients who would benefit from it and which wouldn't so we have many new drugs that that uh are effective sometimes and if we only knew to better select the patients uh for which uh uh the drugs are effective we could have uh gotten approval for them but if you do an all-comer um uh trial uh you would often get a low um uh success rate and you wouldn't be able to prove uh any benefit over standard of care now you know the the pharma companies uh they they face a dilemma because uh if you come to them with a good biomarker you can narrow down the the patient population but obtain um a much higher success rate versus an all-comma trial uh but uh you you would succeed in the trial but you narrow down a priori your your patient population so traditionally pharma companies didn't like uh biomarker uh based trials they didn't like to a priori and narrow down the patient population but uh in recent years more and more of the trials are actually biomarker based and what Tungia offers is a better way more accurate way to develop such biomarkers that would guide the trials and actually we are working to expand the patient population because right now many drugs are going into trials based on some genomic mutation and as we saw these are uh not great biomarkers so you narrow it down to some mutation you have your 30 or 40 percent um success rate within that patient population but if we were able to say okay take only half of the population of patients with this mutation but there's also a 10 or 15 or 20 percent of the patient populations without that mutation that you could also target, that actually leads to a larger patient population with higher accuracy.
Christian SoschnerSo that's the kind of work that we're doing developing more accurate uh biomarkers that would allow you both to enlarge your patient population and get um higher success rates in the clinical trials and and uh we're hoping that uh this would really lead to uh more and better uh approvals in in the upcoming years uh i hope so because i think uh there is uh only little room for a second trial so when a clinical trial failed it's really difficult to i mean it doesn't matter if it's in a private or company or in a in a big pharma company uh it's really difficult then to convince investors or also the the boards in bigger corporations to reinvest in in another trial because it was the wrong patient population.
Christian SoschnerYeah you're absolutely right uh it's it's very very hard to salvage uh failed trials so it's it's uh of crucial importance to to get it right the first time then you can expand to to larger populations etc but but uh I think it it would mean a lot to the whole industry if if we could get more successful um uh first trials and and because right now we're losing many uh potentially uh beneficial drugs that's true um when I think about the RD value chain from um um research uh in research organizations doesn't matter if it's universities or if it's uh pharma companies um up to clinical uh phase three or four studies um what is the ideal point to approach you i mean you your team might be a potential partner as far as I understood uh for any corporation who is uh attempting to develop drugs against cancer um what is your ideal client in that area how early can it be it can be very early so so um and light is is a very very unique uh platform uh in that respect uh and and to understand uh why it is so unique we'll we'll have to dive a little bit deeper into the technology but I can uh easily describe what's the difference uh so you know there are many um AI companies out there which are able to develop good biomarkers um if you have sufficient data so the normal approach would be uh let's say you have a uh a drug I don't know I'm making up uh an example for lung cancer and you've tried it out on a thousand different lung cancer patients and it worked for uh 300 uh of these uh uh thousand patients and and the other 700 did not respond to the drug now if you collected a lot of data you collected the demographics of course and you also collected you did um uh DNA sequencing and and you did messenger RNA sequencing to to measure the expression the transcriptomics you can take all of that data for each patient okay as features for um um supervised learning algorithm and you can take the outcome responder versus non-responder as a label and you can uh train a machine learning algorithm be it a support vector machine or or a logistic regression model or a deep learning model depending on your taste and and uh the specifics of of uh of the problem and you can train it to classify patients based on let's say demographics plus genomics plus transcriptomics into responders versus non-responders and and you can get really good models that way but there is a problem usually you just don't have that data definitely you don't have that data when you're developing a new drug that hasn't yet been tried on even a single patient but even with uh drugs that have been um that passed already phase one or phase one two you only have a handful of patients so numbers are just not big enough to uh train that type of of uh model and and obtain such AI based accurate biomarkers so the uniqueness about what we do in Pangea
Tuvik BekerIs um we actually broke up the the uh the biomarker development uh uh process into two distinct stages. The first stage asks a very general question. Basically, what we are asking is if we hit a particular target, if we have a drug, let's say that inhibits a specific gene, there are many other genes that have functional interactions with that target gene.
Tuvik BekerAnd the state of these uh um of these genes, we we call them the uh functional environment of the target gene. The state of this functional environment would determine if the treatment would be more effective, or on on the other hand, they might cause the cancer cell to overcome the attack, to overcome the treatment, find other pathways to bypass what we are trying to block, for example.
Tuvik BekerOkay, so our uh focus is understanding this functional neighborhood of the genes which are uh the drug targets. And the way we break down the this question is first we ask, can we identify those genes which are uh functionally related in a strong manner to uh to the target gene? So for any pair of genes in the genome, we can ask, are these related in a functional manner?
Tuvik BekerSo just to give an example of such a functional relationship, one famous example is a relationship called uh synthetic lethality. And synthetic lethality is a great example of many things. Among other things, it's a great example of how biologists give complicated names to simple phenomena. Because it it simply means that gene A and gene B, none of them is individually essential, but you have to have at least one of them uh functioning properly.
Tuvik BekerSo if you lose gene A, the cell still functions. If you lose gene B, the cell still functions. But if you lose A and B simultaneously, that would lead to cell death. So for example, we can find such synthetic lethal interactions, and we find them based on um a lot of in vitro data, okay, so data from cell cultures that have been subject to genetic manipulations, to uh drug uh trials, so adding drug to the digensing, how it affects the cells, etc.
Tuvik Bekeretc. And we've got a lot of clinical data, so we have those immense uh databases of clinical data and in vitro data and phylogenetic data, based on which we can find the synthetic lethal interaction and other types of interactions, synthetic uh dosage lethality and synthetic rescue interactions. And we um we are able to draw these large maps of uh functional interactions within the human genome.
Tuvik BekerWe call them the uh genetic um um social graphs, uh so to speak, because uh that they uh describe some some uh relationship between the genes. And the important thing is that this stage does not rely on any information which is specific to uh to one cancer type or to a specific therapy type. So this is the heavy lifting of our AI machinery, and it's not drug specific nor cancer specific.
Tuvik BekerAnd in the next stage, we can look at the activation pattern of a particular uh patient, we can look at their DNA and RNA sequencing results, and superimposing that on our pre-existing map of interactions, we can come up with the enlighten matching score. And the nice thing is that we do that and we don't need any specific uh clinical data for the drug that is being um uh assessed.
Tuvik BekerSo Nlight is able to create biomarkers for completely novel drugs or for drugs that uh are already um that already exist but have only been tried on a handful of patients so far. And all of our results in the various papers are based on this methodology, which was never trained on the specific scenario on which it is tested. So this is a very, very significant uh differentiating factor which allows us to really work with um drug developers starting at very early stages of the development.
Tuvik BekerSo, in theory, you can apply it when the drug is still on the drawing board before a microgram of it uh has ever been produced, and anticipate in advance which patients would benefit from it and which not supposing that you know uh well enough what genes it's going to target or what proteins it's going to target. I hope that's been clear enough. It's uh it's uh a little bit complicated.
Christian SoschnerIt sounds great to me. I mean, I think maybe it's a bad joke, but uh it had in mind it's the matchmaking service then for for drugs and patients basically, so can swipe through and find the right one.
Tuvik BekerIt is, it is in a sense, and and really enlightened produces reports uh which scan through uh um over uh 80 different drugs for each patient, and and uh um and and uh they prioritize them uh by their enlightened matching score. Of course, uh eventually you have to to make the clinical decision, and and the oncologists uh should take the Nlight uh report into consideration together with a lot of other clinical information. But but I I think it's uh um it can be a very useful tool, and and it has actually been already proven um in the clinic.
Tuvik BekerWe've uh produced uh enlighten reports over um the the uh last two years to many uh patients with with uh severe and complicated cancers, and and there have been quite a few uh success stories already, and each of them is really a great joy. Um and and we are about to embark in in very large-scale um prospective clinical trials within light, both in the US together with the National Cancer Institute, part of the NIH in Bethesda, and also in Israel with the Rambam hospital in in Haifa.
Tuvik BekerAnd uh uh soon uh we're hoping to start trials also in in Sheba, which is the largest hospital in Israel, and Hadassah in Jerusalem, which is uh another very large hospital here in Israel. So uh uh 2023 is going to see a lot of uh clinical trial activity around uh and light.
Christian SoschnerAnd hopefully, successful it would be great to to increase the success rate for both women uh drug developers, but also for the patients. I think this is in the end of the day, the uh the ultimate goal to help the patients find the right treatment and uh successfully fight off cancer. Right, right, definitely. What what about the the business model in your area? Uh when if let's start with drug developers, drug development. Um are you uh offering your solutions as a service or are you participating in the clinical trial?
Christian SoschnerWhat's what's your what are your thoughts about the business model of Pangea?
Tuvik BekerYeah, so we we're not thinking about uh Pangea as a services company. We we are the way we see ourselves is is really as true partners for for uh the the drug developers. So we like to uh uh take a share of the risk and also uh a share of the upside. Um but it's uh we try to be uh flexible and um and really find the the uh the right business structure uh to to collaborate with uh our partners, whether they are commercial drug developers or or academic institutions.
Tuvik BekerWe have lots and lots of uh uh academic uh collaborations, both here in Israel and and a lot of them in the US. And we are now talking to a couple of uh uh European partners. We're looking to establish uh also research collaborations in Europe. Uh so it's it's uh uh it's it's pretty varied. Um so uh really the the the idea is to get involved early and and become um an integral part of the uh drug development uh process, bringing our uh unique uh capabilities to to this uh process and and hopefully uh significantly improving the results.
Christian SoschnerSo you become a long-term partner then of the development um in the development process. Yeah, definitely that that's the approach. On one hand, on the other hand, um, I hope I understood it right from your explanation. You might be also a potential partner for cancer hospitals who have uh cancer patients in the hospitals and want to screen the market for uh the best solutions for their patients. Um, what is the what are your thoughts about the business model in that area?
Tuvik BekerSo uh I I right now we are offering this service completely pro bono. So we're not performing the sequencing um uh ourselves, but uh we are happy to run an enlighten report for any patient who has already undergone uh RNA sequencing and and uh potentially also DNA sequencing, but uh it's it's the uh mRNA sequencing that that's the essential and and unique uh um data source for uh the enlighten analysis.
Tuvik BekerAnd and we are doing it uh for a while now in in Israel, and and uh we've recently extended that uh to the US. Um and as I said, we are uh um expecting to begin a large-scale uh clinical trial around that uh together with the with the NCI, with the National Cancer Institute, uh in the fall. Um and eventually I think there is a huge commercial potential there, but but we're not there yet.
Tuvik BekerAnd and uh I wouldn't uh I wouldn't like to speculate on what exactly uh the monetization model would be around that. There are many different ways to to go around it. It's very important for us to bring this solution uh to the market because uh you know, beyond its uh its obvious uh economic value, uh it's first and foremost a solution that can really uh make make uh significant impact on patients' lives.
Tuvik BekerSo I'm I'm sure we'll find a way to also uh make money out of that uh down the road. And we're definitely looking at different solutions, but uh let's first uh get it uh uh out there and and get uh many patients uh tested and and uh uh prove the value at a large scale. And I'm sure that economic success would would follow eventually.
Christian SoschnerThat's true. That's true. What about what about your team? Uh, how big is uh Pangea currently and uh who are the team players?
Tuvik BekerOkay, so so Pangea is is around uh 20 people. Uh at the time we're still uh a small company, uh, but uh we we have a very, very unique and and uh a very strong team. Um uh the the company is uh heavily oriented uh towards RD, so uh most of the team is uh a very very strong um uh RD team, and we have uh um uh many PhDs and and uh uh master degree uh holders uh both in biology and in computer science, machine learning, uh data science, statistics, etc.
Tuvik BekerSo we span um a range of of uh uh specialties that that uh cover um uh precision oncology from from multiple uh angles. And we've been really fortunate to uh to recruit such uh wonderful people. And uh it's uh I think it's really the most important thing for uh for Punjia to be able to continue to recruit such uh such amazing people to our team.
Christian SoschnerSounds sounds amazing. Sounds amazing. Um we're coming to the end of uh our conversation. Uh let me ask you two final questions. Uh, one is what do you need currently? What are you looking for? What is your next step that uh someone from the audience might help you with?
Tuvik BekerWell, first of all, uh every uh startup company needs more money. It's it's uh it's trivial, it's obvious. Uh we will uh we will need more money. By the way, we we uh we haven't released that yet, so I won't provide too many details, but I can tell you that we've uh recently increased our uh seed funding by by another uh five million dollars, uh bringing the the total raised so far to uh to over uh 12 million dollars.
Tuvik BekerAnd um this this was important for us, uh especially right now, because as I said before, it looks like we are um uh during a uh somewhat of a downturn in the economy. No one knows how long it would last, but uh it's not as easy to to raise money uh uh today as as it was uh six or or nine months ago. So this gives us a um uh really nice uh uh security and and and safety net and enables us to continue expanding uh uh for for a long period of time.
Tuvik BekerUm and uh the other thing that that we are looking for, we are looking for uh collaborations and so especially uh to the uh uh European audience, we we don't have as many European collaborations uh right now as uh uh as we would like to have. Uh and and we really are looking for uh partners in Europe, both uh hospitals and and uh universities and of course uh uh pharma companies.
Tuvik BekerSo uh do feel free to uh to reach out. We are actively seeking uh collaboration with uh organizations from Europe, and uh we would uh we would love to discuss uh the possibilities of collaboration.
Christian SoschnerThat's great. So my final question is uh you're an experienced founder and uh you've built multiple companies to success and uh also are now in the process of uh building the next uh great company in the life science industry. Uh when a young founder approaches you, a first-time founder approaches you and asks for advice, and you only have one minute to give one advice, what would it be?
Tuvik BekerWell, first of all, I I I usually try to have more than one minute. Uh uh, so I I I don't believe in in uh in miracle answers and and really uh every case is different, and uh uh the challenges that uh uh every young entrepreneur uh or beginning entrepreneur doesn't have to be uh young um uh faces are are different. Uh so I wouldn't try to to come up with uh one size fits all advice that uh entrepreneurs are are always uh welcome to uh to get in touch.
Tuvik BekerAnd and I I try to to uh find time to uh to meet and and discuss and uh hope to the limited ability I have.
Christian SoschnerThat's a great answer. Tubik, did I miss anything? Is there any topic open that you would like to talk about or any question that you want me to uh want me to ask you?
Tuvik BekerNo, it's it's been a pretty long uh meeting and and very enjoyable one and and definitely uh a thorough one. So um I I I would really like to take the opportunity to thank you again for for uh inviting me on on this podcast. And uh it's been wonderful. Uh thanks a lot and and keep on this uh wonderful work.
Christian SoschnerThank you very much. I enjoyed the conversation as well, and it was great having you on the show. I wish you and your team uh success and uh luck in the coming years, and I'm pretty sure that you improve cancer research. I hope so too. Thank you very much. Thank you. Have a great day. Bye. Bye bye, Christian. Bye. Did you enjoy the episode? Then please subscribe and follow the channel.
Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...
The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...
In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...
A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...
What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...